Resources

Dr. Ralph Defronzo talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the necessity of being proactive in the treatment of prediabetes.

Dr. Ralph Defronzo talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the success of triple therapy in the treatment of diabetes.

Dr. Ralph Defronzo talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the effects of certain medication on beta cell preservation and regeneration.

As we know, the most ineffective medication is the one needed but never taken. There are many reasons our patients don’t take prescription medicines, but a biggy is the cost. If a medicine is too expensive, the patient will not fill the prescription, therefore won’t take it. For example, when ordering an SGLT-2 and/or GLP-1, each can cost hundreds or more for a month’s prescription. Some are covered for both. Some are covered for one brand, but not the other.

In this Exclusive Interview, Dr. Fernando Guerrero discusses the usefulness of magnesium in the treatment of diabetes.

Dr. Guerrero discusses his work in magnesium research and the relationship between magnesium and diabetes and glucose metabolic disorders in diabetes.

In this week's Homerun Slides, the current therapy for type 2 diabetes.

The fed state is the absorptive period between meals. Carbohydrates are normally mixed with lipids and protein in the diet and make up 40 – 60% of the caloric content. Absorption of dietary carbohydrates is influenced by their chemical form (refined sugars or complex carbohydrates) and by other components of food. Furthermore, disposition of dietary carbohydrate is indirectly affected by fats and protein to the extent that these latter (i) compete with glucose as substrates, and (ii) interfere with glucoregulatory hormones by altering insulin secretion.

Why Google, Apple, and Amazon entering the diabetes market is the real big story from ADA.

Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.